News Center
EWHA NEWS
Health Convergence Professor Publishes Article in JAMA
Ahn Song Vogue, a professor of Health Convergence published an article in the world-renowned medical journal JAMA (Journal of the American Medical Association). In a joint research with researchers from Gachon University College of Medicine and Harvard Medical School, Professor Ahn analyzed the incidence of thyroid cancer, the number and types of thyroid cancer surgeries and the incidence of postoperative hypoparathyroidism in Korea between 2007 and 2016, based on the big data from the National Health Insurance Sharing Service (NHISS) which is operated by the National Health Insurance Service (NHIS) of Korea. Thyroid cancer had been increasing at a faster rate than any other cancer since 2000 in both Korea and worldwide. Compared with the incidence of thyroid cancer by country in 2012, South Korea showed four times higher incidence of thyroid cancer in men and five times in women than the United States, which is known to be related to high rate of medical screenings. Since 2013, with much heightened awareness of situations like this, new guidelines have been enacted and implemented to encourage more selective thyroid ultrasonography at the time of examining for thyroid cancer, and to revise the criteria for a thyroid fine needle aspiration cytology with suspicious nodules larger than 1 cm in diameter. The research found that the incidence and the rate of surgeries of thyroid cancer began to decline after peaking in 2013, and that the incidence of postoperative hypoparathyroidism reduced at the same time. Professor Ahn, the first author of the article, said, "This research is meaningful in that it may influence the national health policy by grasping the status and prospect of the national health level and the medical conduct based on the NHISS big data in line with the Fourth Industrial Revolution trend.
Professor Kim Wankyu Succeeded in Attracting Five-Billion-Won-Investment in His Big Data-AI-Based Drug Discovery Venture
Professor Kim Wankyu of Life Science attracted Series A investment worth 5 billion won for KaiPharm, an AI-Data driven drug discovery venture. Professor Kim raised series A investment funding just in 14 months after he set up the venture firm, and plans to build a globally unique reference database for drug-induced gene expression profiles. Kaipharm, which was founded by a research team led by Professor Kim Wankyu in 2018, develops the next generation platform for new medicines through unique bioinformatics analysis, big data mining and virtual search technology. Kim said that, with this technology, we can treat cells with drugs to analyze the expression patterns of approximately 20,000 human genes, and thereby produce a wealth of information on the mechanism of action of the drugs. In addition, the technology can be utilized to find a new indication by investigating whether a change in transcriptome patterns of a developing drug is similar to the action of an existing drug, or by comparing that with the pattern in the state of a particular disease. With this investment, KaiPharm and Institut Pasteur Korea decided to jointly generate an NGS-driven drug-induced transcriptome database (KMAP project). Based on this project, KaiPharm plans to develop new drugs in collaboration with research institutes, universities and pharmaceutical companies at home and abroad and provide analysis services. Previously, KaiPharm was selected as a recipient of Tech Incubator Program for startup Korea (TIPS) by the Ministry of SMEs and Startups and received seed investment. With the Series A investment funding that the firm raised from KB Investment and other six entities, now KaiPharm secures a total of 7 billion won. KaiPharm was established through a startup support program for faculty which includes “Ewha labs venture certification” and provision of a startup space within the laboratory. The firm has actively engaged in student employment and startup for students and recruited three undergraduates as interns during this winter session alone, contributing to nurturing talents. Kim said, “It has been ten years since I joined Ewha. During the first five years, I conducted research on genomics, bioinformatics and systems biology, which are my major field of study. Over the last five or six years, I focused on combining my previous research with development of new drugs, which led to the establishment of a venture firm.” "I want to contribute to bringing innovation to drug development through the convergence of data science and biomedical science," he added. Over the last couple of years, the Department of Life Science saw excellent members of the faculty launching a startup company, including Kang Sang Won (Vastera, inflammatory regulation), Bae Yun Soo (Celros Biotech, vascular disease treatment), and Shim Hyunbo (Curocell, Anticancer immunotherapy).
![[역사DNA] 그땐 그랬지 #1 신촌 캠퍼스의 상징, 본관 #신촌캠퍼스_첫건물 #국가등록문화재_제14호 #본관 #그땐그랬지 #신촌캠퍼스 #이화의상징 #역사DNA #이화여자대학교 #이화여대 #이대 #EWHA #UNIV 이미지](https://scontent.xx.fbcdn.net/v/t51.2885-15/84569565_1898213233656349_6356796635889156069_n.jpg?_nc_cat=106&_nc_ohc=vlk7A1csJTMAX-7lXig&_nc_ht=scontent.xx&oh=5a8039e0ee0cc4b015b1bfbcdc468b64&oe=5E76CA3B)
